Cybin Inc. (CYBN)

Name: Cybin Inc. (CYBN) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Cybin Inc. (CYBN)

Stock Card

$5.64

$-2.25 (-28.52%)

As on 06-Mar-2026 09:30EDT

Market cap

$413 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Value Research Rating

Quality Score

Growth Score

Valuation Score

Momentum Score

Know more

Explore 5 star rated stocks

Cybin (CYBN) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 5.27 High: 6.80

52 Week Range

Low: 4.81 High: 9.83

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-3.8
Debt to Equity

--
Book Value

$--
EPS

$--
Face value

--
Shares outstanding

49,894,131

5 Years Aggregate

CFO

CA$-111.75 Mln

EBITDA

CA$-148.61 Mln

Net Profit

CA$-145.73 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Cybin (CYBN)	-35.9	-10.5	-12.4	-32.8	-33.1	-34.6	--
BSE Sensex^*	-9.3	-1.5	2.7	-3.8	5.7	6.2	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 06-Mar-2026 | *As on 31-Aug-2026 | #As on 26-Oct-2023

Company	2025	2023	2022	2021
Cybin (CYBN)	-7.3	38.0	-75.3	-19.5
S&P Small-Cap 600	4.0	13.9	-17.4	25.3
BSE Sensex	9.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Cybin (CYBN)	5.2	413.1	-131.6	--	-61.8	--	1.0
Bright Minds Biosciences Inc (DRUG)	72.8	714.4	-24.8	--	-12.4	--	3.3
Oncolytics Biotech - ADR	0.9	109.2	-38.2	--	--	--	1,055.0

Shareholding Pattern

View Details

About Cybin (CYBN)

Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat... major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada. Read more

Co-Founder, President & Executive Chairman

Mr. Eric So L.L.B.
Co-Founder, President & Executive Chairman

Mr. Eric So L.L.B.
Headquarters

Toronto, ON
Website

https://cybin.com

FAQs for Cybin (CYBN)

What is the current share price of Cybin Inc (CYBN) Today?

The share price of Cybin Inc (CYBN) is $5.64 (NYSE) as of 06-Mar-2026 09:30 EDT. Cybin Inc (CYBN) has given a return of -33.05% in the last 3 years.

What is the current PB & PE ratio of Cybin Inc (CYBN)?

Since, TTM earnings of Cybin Inc (CYBN) is negative, P/E ratio is not available.
The P/B ratio of Cybin Inc (CYBN) is 1.03 times as on 06-Mar-2026, a 66 discount to its peers’ median range of 3.07 times.

PE & PB ratio at the end of financial year.